DAPA-HF | ACROSS T2D

DAPA-HF

The DAPA-HF trial assessed the efficacy and safety of dapagliflozin in patients with heart failure and a reduced ejection fraction, with or without diabetes. This module details the results.

DAPA-HF

DAPA-HF
DAPA-HF
Login or create an account to see restricted content
DAPA-HF
Login or create an account to see restricted content
DAPA-HF: trial design^1,2
Login or create an account to see restricted content
DAPA-HF: key inclusion and exclusion criteria^1,2
Login or create an account to see restricted content
DAPA-HF: hierarchical analysis plan^1,2
Login or create an account to see restricted content
DAPA-HF: hypothesis testing outcomes and subsequent analysis^1,2
Login or create an account to see restricted content
DAPA-HF: baseline characteristics (1/2)
Login or create an account to see restricted content
DAPA-HF: baseline characteristics (2/2)
Login or create an account to see restricted content
DAPA-HF: baseline medication
Login or create an account to see restricted content
DAPA-HF
Login or create an account to see restricted content
DAPA-HF: primary composite outcome of worsening HF* or CV death (1/2)
Login or create an account to see restricted content
DAPA-HF: primary composite outcome of worsening HF* or CV death (2/2)
Login or create an account to see restricted content
DAPA-HF: CV death
Login or create an account to see restricted content
DAPA-HF: hospitalisation for heart failure
Login or create an account to see restricted content
DAPA-HF: primary composite outcome* by prespecified subgroups (1/3)
Login or create an account to see restricted content
DAPA-HF: primary composite outcome* by prespecified subgroups (2/3)
Login or create an account to see restricted content
DAPA-HF: primary composite outcome* by prespecified subgroups (3/3)
Login or create an account to see restricted content
DAPA-HF: primary composite outcome* in patients with or without T2D at baseline
Login or create an account to see restricted content
DAPA-HF
Login or create an account to see restricted content
DAPA-HF: secondary efficacy outcomes
Login or create an account to see restricted content
DAPA-HF: all-cause mortality
Login or create an account to see restricted content
DAPA-HF: secondary outcome of change in KCCQ total symptom score
Login or create an account to see restricted content
DAPA-HF
Login or create an account to see restricted content
In DAPA-HF, the effect of dapagliflozin on CV and HHF outcomes was generally consistent between patients with or without T2D at baseline
Login or create an account to see restricted content
Effects of dapagliflozin in CV death and HHF were consistent regardless of background therapy and dose in DAPA-HF
Login or create an account to see restricted content
DAPA-HF
Login or create an account to see restricted content
DAPA-HF: metabolic parameters
Login or create an account to see restricted content
DAPA-HF
Login or create an account to see restricted content
DAPA-HF: safety summary
Login or create an account to see restricted content
DAPA-HF
Login or create an account to see restricted content
DAPA-HF: summary^1,2
Login or create an account to see restricted content
DAPA-HF: patient population